stockrowTransMedics Group, Inc.
TMDX Healthcare Medical Devices
TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −31.0%
- Free cash flow
- −55.4%
- Total debt
- −89.3%
Quarter to September 2026, against a year earlier
Follow TMDX
Alert me
TransMedics Group, Inc. (TMDX) Net income
TransMedics Group, Inc.'s net income for fiscal 2025 was $190.3M, up 436.6% from $35.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was $144.5M. Over the past ten years it has ranged from −$44.2M (fiscal 2021) to $190.3M (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 4 consecutive fiscal years. TransMedics Group, Inc. ranks 18th of 149 Medical Devices companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $190.3M | 436.58% |
| FY2024 | $35.5M | — |
| FY2023 | −$25.0M | — |
| FY2022 | −$36.2M | — |
| FY2021 | −$44.2M | — |
| FY2020 | −$28.7M | — |
| FY2019 | −$33.5M | — |
| FY2018 | −$23.8M | — |
| FY2017 | $0.00 | — |
| FY2016 | −$24.1M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $17.1M | 16.29% |
| Jun 2026 | $14.7M | 100.71% |
| Mar 2026 | $7.3M | (93.06%) |
| Dec 2025 | $105.4M | 333.34% |
| 31 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TMDX TransMedics Group, Inc. | $144.5M |
| INSP Inspire Medical Systems, Inc. compare | $100.7M |
| UFPT UFP Technologies, Inc. compare | $72.3M |
| AXGN AxoGen, Inc. compare | −$31.9M |
| ESTA Establishment Labs Holdings Inc. compare | −$38.9M |
| BFLY Butterfly Network, Inc. compare | −$53.7M |
| NEOG Neogen Corporation compare | −$56.1M |
| ALMR Alamar Biosciences, Inc. compare | −$77.7M |
| NVCR NovoCure Limited compare | −$121.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on TMDX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement